Literature DB >> 23190226

Ponatinib for chronic myeloid leukemia.

John M Goldman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23190226     DOI： 10.1056/NEJMe1210796

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Evolution of acquired resistance to anti-cancer therapy.

Authors:  Jasmine Foo; Franziska Michor
Journal:  J Theor Biol       Date:  2014-03-25       Impact factor: 2.691

2.  UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

Authors:  Sandra Christoph; Deborah Deryckere; Jennifer Schlegel; J Kimble Frazer; Lance A Batchelor; Alesia Y Trakhimets; Susan Sather; Debra M Hunter; Christopher T Cummings; Jing Liu; Chao Yang; Dmitri Kireev; Catherine Simpson; Jacqueline Norris-Drouin; Emily A Hull-Ryde; William P Janzen; Gary L Johnson; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Douglas K Graham
Journal:  Mol Cancer Ther       Date:  2013-08-30       Impact factor: 6.261

3.  Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells.

Authors:  Angela Proctor; Imola G Zigoneanu; Qunzhao Wang; Christopher E Sims; David S Lawrence; Nancy L Allbritton
Journal:  Analyst       Date:  2016-10-17       Impact factor: 4.616

Review 4.  Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

Review 5.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

Review 6.  Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Authors:  Andrew M Bellinger; Carlos L Arteaga; Thomas Force; Benjamin D Humphreys; George D Demetri; Brian J Druker; Javid J Moslehi
Journal:  Circulation       Date:  2015-12-08       Impact factor: 29.690

7.  What challenges remain in chronic myeloid leukemia research?

Authors:  Angelo M Carella; Susan Branford; Michael Deininger; Francois X Mahon; Giuseppe Saglio; Anna Eiring; Jamshid Khorashad; Thomas O'Hare; John M Goldman
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

8.  Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.

Authors:  Yue-Li Sun; Priyank Kumar; Kamlesh Sodani; Atish Patel; Yihang Pan; Maria R Baer; Zhe-Sheng Chen; Wen-Qi Jiang
Journal:  Oncol Rep       Date:  2014-01-28       Impact factor: 3.906

9.  Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.

Authors:  Peter Canning; Li Tan; Kiki Chu; Sam W Lee; Nathanael S Gray; Alex N Bullock
Journal:  J Mol Biol       Date:  2014-04-23       Impact factor: 5.469

10.  Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.

Authors:  Yasufumi Matsuda; Takahiro Yamauchi; Naoko Hosono; Kanako Uzui; Eiju Negoro; Koji Morinaga; Rie Nishi; Akira Yoshida; Shinya Kimura; Taira Maekawa; Takanori Ueda
Journal:  Cancer Sci       Date:  2016-06-21       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.